Cor Therapeutics, Inc.

Gilead Calistoga LLC

University of California

Neill A Giese

Nathalie Lokker

Lewis T Williams

W Michael Gallatin

David Lawrence Wolf

Jaime A Escobedo

Brian Lannutti

Roger G Ulrich

Larry J Fretto

James E Tomlinson

Langdon Miller

Thomas M Jahn

Robert M Scarborough

Jerry B Evarts

Kamal Deep Puri

Alan M Laibelman

The invention provides methods that relate to a novel therapeutic strategy for the treatment of hematological malignancies and inflammatory diseases. In particular, the method comprises administering a compound of formula A, 

Therapies for hematologic malignancies

The invention provides methods that relate to a novel therapeutic strategy for the treatment of hematological malignancies and inflammatory diseases. In particular, the method comprises administration of a compound of formula A, 

The invention provides methods that relate to a novel therapeutic strategy for the treatment of hematological malignancies and inflammatory diseases. In particular, the method comprises administration of a compound of formula I, 

Methods of treatment for solid tumors

A method for selectively inhibiting a kinase is disclosed, which comprises contacting a composition containing a kinase with a compound of the formula: ##STR1## wherein: R.sub.1 is lower alkyl, lower hydrocarbyl, aryl lower alkyl, heteroaryl lower alkyl, 5- or 6-membered heterocyclic aromatic, polyaromatic, polyaromatic carbonyl, polyheteroaromatic or polyheteroaromatic carbonyl; R.sub.2 is lower alkyl, lower hydrocarbyl, aryl lower alkyl, heteroaryl lower alkyl, 5- or 6-membered heterocyclic aromatic, lower hydrocarboyl, 5- or 6-membered heterocyclic aromatic carbonyl, polyaromatic or polyheteroaromatic; R.sub.3 is H or lower alkyl; R.sub.5 is H, lower alkyl, lower hydrocarbyl, aryl lower alkyl, heteroaryl lower alkyl, 5- or 6-membered heterocyclic aromatic, halogen, or cyano; and R.sub.6 is H or lower hydrocarboyl.

Pharmaceutical pyrazole compositions useful as inhibitors of protein

Defined constructs of modified human platelet-derived growth factor receptor polypeptides are provided. Extracellular region domain structures are identified and modifications and combinatorial rearrangements of the receptor segments are provided. Both cell bound and soluble forms of modified segments are made available, as are methods for assays using them, allowing for screening of ligand analogues.

Methods of using domains of extracellular region of human

This invention provides antibodies that bind to epitopes of human platelet-derived growth factor receptor (hPDGF-R) fragments, wherein the fragments comprise one or more platelet-derived growth factor (PDGF) ligand binding regions from extracellular domains D1, D2, and D3. Also provided are antibodies specific for domain D3, such as monoclonal antibodies directed to the intra-cysteine portion of domain D3.

Human platelet-derived growth factor receptor extracellular domain

A method for selectively inhibiting a kinase is disclosed, which comprises contacting a composition containing a kinase with a molecule of the formula ##STR1## wherein R.sub.1 is H, lower alkyl, or lower alkanoyl; R.sub.2 is H, lower alkyl, or lower alkanoyl; R.sub.3 and R.sub.4 together represent a cis double bond or --O-- or each of R.sub.3 and R.sub.4 independently represents H or OR; R.sub.5 is .dbd.O, .dbd.S, or --H, --OR; R.sub.6 and R.sub.7 together represent a double bond or --O-- or each of R.sub.6 and R.sub.7 independently represents H or OR; R.sub.4 and R together represent a double bond or --O-- or each of R.sub.8 and R.sub.9 independently represents H or OR; and each R independently represents H, lower alkyl, or lower alkanoyl.

Method and compositions for inhibiting protein kinases

A method for selectively inhibiting a kinase is disclosed, which comprises contacting a composition containing a kinase with a molecule of the formula ##STR1## wherein R.sub.1 is H, lower alkyl, or lower alkanoyl; R.sub.2 is H, lower alkyl, or lower alkanoyl; R.sub.3 and R.sub.4 together represent a cis double bond or --0-- or each of R.sub.3 and R.sub.4 independently represents H or OR; R.sub.5 is .dbd.O, .dbd.S, or --H, --OR; R.sub.6 and R.sub.7 together represent a double bond or --O-- or each of R.sub.6 and R.sub.7 independently represents H or OR; R.sub.8 and R.sub.9 together represent a double bond or --O-- or each of R.sub.8 and R.sub.9 independently represents H or OR; and each R independently represents H, lower alkyl, or lower alkanoyl.

Domains of extracellular region of human platelet derived growth factor

A method for selectively inhibiting a kinase is disclosed, which comprises contacting a composition containing a kinase with a molecule of the formula ##STR1## wherein R.sub.1 is H, lower alkyl, or lower alkanoyl; R.sub.2 is H, lower alkyl, or lower alkanoyl; R.sub.3 and R.sub.4 together represent a cis double bond or --O-- or each of R.sub.3 and R.sub.4 independently represents H or OR; R.sub.5 is .dbd.O, .dbd.S, or --H, --OR; R.sub.6 and R.sub.7 together represent a double bond or --O-- or each of R.sub.6 and R.sub.7 independently represents H or OR; R.sub.8 and R.sub.9 together represent a double bond or --O-- or each of R.sub.8 and R.sub.9 independently represents H or OR; and each R independently represents H, lower alkyl, or lower alkanoyl.

Growing community of inventors

San Francisco, CA, United States of America

Neill A Giese